Goksel G.Taneli F.Uslu R.Ulman C.Dinc G.Coskun T.Kandiloglu A.R.2024-07-222024-07-22200703000605http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19443This study was conducted to investigate the serum levels of her-2/neu and survivin in patients with early-stage breast cancer and their relationship with known histological parameters. Forty-one patients with early-stage breast cancer were investigated. Serum samples were collected from patients on their first admission before adjuvant chemotherapy, and from healthy controls. Serum her-2/neu and survivin levels were determined using an enzyme-linked immunosorbent assay. There was no difference in the levels of serum her-2/neu and survivin between the breast cancer patients and the control group. Serum her-2/neu concentration showed moderate correlations with disease stage and the Ki-67 level, and the serum survivin level showed a moderate correlation with progesterone receptor concentration. Serum levels of her-2/neu and survivin were not significantly related to age and histological parameters in patients with early-stage breast cancer. However, much research continues on the prognostic value of serum her-2/neu and survivin levels, and important new knowledge may ultimately emerge. Copyright © 2007 Cambridge Medical Publications.Englishepidermal growth factor receptor 2Ki 67 antigenprogesterone receptorsurvivinadultagearticlebreast cancercancer adjuvant therapycancer chemotherapycancer stagingclinical articlecontrolled studyearly cancerenzyme linked immunosorbent assayfemalehistopathologyhumanhuman tissueprotein blood levelArticle10.1177/147323000703500201